GlassScriptPhysician profile
Megan Castillo
NPI 1447781091
$8,053.49
in general payments reported to CMS, 2019-2025
31 companies · $3,897 in 2025
The $3,897 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $110 · 2023: $26.99 · 2024: $3,714 · 2025: $3,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,602 · Education: $36.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,602.32 |
| Education | $36.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,967.87 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $825.04 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $661.05 | 2024-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $516.47 | 2024-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $466.35 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $426.59 | 2024-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $391.52 | 2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $346.66 | 2024-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $291.94 | 2024-2025 | |
| Ardelyx, INC. | $283.50 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $275.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $239.36 | 2024-2025 | Vowst, Zenpep |
| Intercept Pharmaceuticals, INC. | $185.77 | 2024-2025 | |
| Celltrion USA INC. | $145.92 | 2024-2025 | Vegzelma, Zymfentra |
| Astrazeneca Pharmaceuticals LP | $122.31 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $118.90 | 2024 | Zeposia |
| Melinta Therapeutics, LLC | $109.54 | 2022 | |
| Braintree Laboratories, INC. | $106.35 | 2024-2025 | Suflave, Sutab |
| Janssen Pharmaceuticals, INC | $104.97 | 2021 | |
| Pfizer INC. | $77.89 | 2021 | |
| Novo Nordisk INC | $69.79 | 2025 | Wegovy |
| Lilly USA, LLC | $45.19 | 2024-2025 | Omvoh |
| Celgene Corporation | $43.47 | 2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $43.43 | 2024 | |
| Ferring Pharmaceuticals INC. | $41.29 | 2024-2025 | Rebyota |
| Evoke Pharma, INC. | $33.09 | 2025 | |
| Boston Scientific Corporation | $26.99 | 2023 | Watchman Access System |
| Mallinckrodt Hospital Products INC. | $26.82 | 2025 | Terlivaz |
| Exact Sciences Corporation | $22.99 | 2024 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $22.80 | 2025 | Givlaari |
| Vivus LLC | $13.75 | 2025 | Pancreaze |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.